12:00 AM
 | 
Jan 28, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NX-1207: Phase III data

The open-label, U.S. Phase III NX02-0020 trial in 192 men with BPH who previously received a single 2.5 mg injection of NX-1207 in a prior Phase II or Phase III trial showed that a second injection of NX-1207 met the 6-month primary safety endpoint with no significant treatment-related...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >